XYLT2 and cancer: Altogether, these reports and our observations of remarkable similarities between SOS-less and RAS-less cells27,28,37 prompted us to postulate that SOS proteins may constitute valuable therapeutic targets in RTK-RAS-dependent cancers such as LUAD.